Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronald de Wit

Showing results (21-30 of 204) with videos related to

Pageof 21
Sort By:
BMC Medicine|December 24, 2015
Irrefutable evidence for the use of docetaxel in newly diagnosed metastatic prostate cancer: results from the STAMPEDE and CHAARTED trialsRobert J van Soest, Ronald de Wit
Cancers|July 29, 2023
Immunotherapy in Urothelial Cancer: Stop When Achieving a Response, Restart upon Disease ProgressionYoussra Salhi, Ronald De Wit, Debbie Robbrecht
Cancer Chemotherapy and Pharmacology|April 20, 2005
Is there a pharmacological basis for differences in 5-HT3-receptor antagonist efficacy in refractory patients?Ronald de Wit, Matti Aapro, Peter R Blower
The New England Journal of Medicine|March 27, 2020
Cabazitaxel in Metastatic Prostate Cancer. ReplyRonald de Wit, Johann de Bono, Daniel Castellano
European Journal of Cancer (Oxford, England : 1990)|September 25, 2009
Chemotherapy in patients with castration-resistant prostate cancerHielke J Meulenbeld, Paul Hamberg, Ronald de Wit
Critical Reviews in Oncology/Hematology|May 14, 2005
Drug-drug interactions in oncology: why are they important and can they be minimized?Peter Blower, Ronald de Wit, Susan Goodin, et al.
BJU International|October 21, 2009
Management of good risk germ-cell tumoursMonique M Troost, Cora N Sternberg, Ronald de Wit
European Journal of Cancer (Oxford, England : 1990)|July 26, 2008
The management of cerebral metastasis from germ cell cancer; walking the tightropeRonald de Wit, Martin van den Bent, Wim Kirkels
The Lancet. Oncology|September 3, 2021
Pembrolizumab monotherapy for high-risk, non-muscle invasive bladder cancer - Authors' replyArjun V Balar, Ashish M Kamat, Ronald de Wit, et al.
European Urology|July 12, 2014
Re: Nader Al Nakouzi, Sylvestre Le Moulec, Laurence Albigès, et al. Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapies. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2014.04.015Robert J van Soest, Ronald de Wit, Wytske M van Weerden
Pageof 21

Showing results (21-30 of 204) with videos related to

Sort By:
Pageof 21
BMC Medicine|December 24, 2015
Irrefutable evidence for the use of docetaxel in newly diagnosed metastatic prostate cancer: results from the STAMPEDE and CHAARTED trialsRobert J van Soest, Ronald de Wit
Cancers|July 29, 2023
Immunotherapy in Urothelial Cancer: Stop When Achieving a Response, Restart upon Disease ProgressionYoussra Salhi, Ronald De Wit, Debbie Robbrecht
Cancer Chemotherapy and Pharmacology|April 20, 2005
Is there a pharmacological basis for differences in 5-HT3-receptor antagonist efficacy in refractory patients?Ronald de Wit, Matti Aapro, Peter R Blower
The New England Journal of Medicine|March 27, 2020
Cabazitaxel in Metastatic Prostate Cancer. ReplyRonald de Wit, Johann de Bono, Daniel Castellano
European Journal of Cancer (Oxford, England : 1990)|September 25, 2009
Chemotherapy in patients with castration-resistant prostate cancerHielke J Meulenbeld, Paul Hamberg, Ronald de Wit
Critical Reviews in Oncology/Hematology|May 14, 2005
Drug-drug interactions in oncology: why are they important and can they be minimized?Peter Blower, Ronald de Wit, Susan Goodin, et al.
BJU International|October 21, 2009
Management of good risk germ-cell tumoursMonique M Troost, Cora N Sternberg, Ronald de Wit
European Journal of Cancer (Oxford, England : 1990)|July 26, 2008
The management of cerebral metastasis from germ cell cancer; walking the tightropeRonald de Wit, Martin van den Bent, Wim Kirkels
The Lancet. Oncology|September 3, 2021
Pembrolizumab monotherapy for high-risk, non-muscle invasive bladder cancer - Authors' replyArjun V Balar, Ashish M Kamat, Ronald de Wit, et al.
European Urology|July 12, 2014
Re: Nader Al Nakouzi, Sylvestre Le Moulec, Laurence Albigès, et al. Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapies. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2014.04.015Robert J van Soest, Ronald de Wit, Wytske M van Weerden
Pageof 21